We have also shown that inhibition of ATX, using a type IV inhibitor Cpd17, ameliorates fibrosis, inflammation, and steatosis in HSCs and macrophages in vitro, as well as in NASH and liver cirrhosis mouse models. The gene discussed is ENPP2; the disease is steatosis.